ETIDIOH - NEW

Summary Background Latin America has been experiencing an Oropouche virus (OROV) outbreak of unprecedented magnitude and spread since 2023–24 for unknown reasons. We aimed to identify risk predictors of and areas at risk for OROV transmission. Methods In this multidisciplinary, laboratory-based, modelling study, we retrospectively tested anonymised serum samples collected between 2001 and 2022 for studies on virus epidemiology and medical diagnostics in Bolivia, Brazil, Colombia, Costa Rica, Ecuador, and Peru with nucleoprotein-based commercial ELISAs for OROV-specific IgG and IgM antibodies. Serum samples positive for IgG from different ecological regions and sampling years were tested against Guaroa virus and two OROV glycoprotein reassortants (Iquitos virus and Madre de Dios virus) via plaque reduction neutralisation testing (PRNT) to validate IgG ELISA specificity and support antigenic cartography. Three OROV strains were included in the neutralisation testing, a Cuban OROV isolate...

Abstract Background The recent surge in incidence and geographic spread of OROV infections poses an escalating threat to global public health. However, studies exploring the clinical signs of OROV infection remains exceedingly limited. Methods We searched for OROV studies published until June 17, 2024, in several electronic databases including MEDLINE, EMBASE, SCOPUS, and the Cochrane Library. Results In total, 15 studies involving 806 patients with OROV infection were eligible for inclusion. General symptoms with fever and headache were the most common. Gastrointestinal disturbances like nausea/vomiting, anorexia , and odynophagia were also prevalent, along with ocular symptoms , mainly retro-orbital pain, photophobia, and redness . Respiratory symptoms , such as cough, sore throat and nasal congestion, are present, and skin-related issues like rash, pruritus, and pallor were also identified. Conclusion Overall, this study provides a foundational understanding of OROV’s clinical manif...

Abstract Oropouche fever is caused by the Oropouche virus (OROV; Bunyaviridae , Orthobunyavirus), one of the most frequent arboviruses that infect humans in the Brazilian Amazon . This year, an OROV outbreak was identified in Brazil , and its vertical transmission was reported, which was associated with fetal death and microcephaly. We describe the clinical manifestations identified in three cases of congenital OROV infection with confirmed serology (OROV-IgM) in the mother-newborn binomial . One of the newborns died , and post-mortem molecular analysis using real-time RT-qPCR identified the OROV genome in several tissues . All three newborns were born in the Amazon region in Brazil , and the mothers reported fever, rash, headache, myalgia, and/or retro-orbital pain during pregnancy . The newborns presented with severe microcephaly secondary to brain damage and arthrogryposis , suggestive of an embryo/fetal disruptive process at birth . Brain and spinal images identified overlapping su...

Abstract Given recent outbreaks of Oropouche virus in Latin America and >100 confirmed travel-associated cases in the United States , we evaluated the competence of US vectors , including Aedes albopictus, Culex quinquefasciatus, Culex pipiens , and Anopheles quadrimaculatus mosquitoes . Results with historic and recent isolates suggest transmission potential for those species is low . Source: Emerging Infectious Diseases Journal,  https://wwwnc.cdc.gov/eid/article/31/3/24-1886_article _____

{Extract} Since late 2023, more than 10 000 locally acquired cases of Oropouche virus have been reported in the Americas .1 Here, we describe the first cluster of Oropouche virus imported into France from Cuba , where transmission has been ongoing since at least May, 2024.2 Oropouche virus infection was documented in a group of five women (patients 1–5, confirmed cases) travelling to Cuba with two infants (patients 6–7, suspect cases) between July 28 and Aug 14, 2024. During their stay, patients 1–5 developed a dengue-like syndrome lasting 2–11 days, presenting symptoms similar to those described in the literature for Oropouche virus infection (appendix p 8).3 After recovery, patients 1, 2, and 5 experienced symptom relapse upon their return to France; the observed relapse rate aligns with recent estimates suggesting that 60% of patients with Oropouche virus experience a biphasic illness (appendix pp 7–8).4 During relapse, patient 1 sought medical advice, becoming the first diagnosed O...